Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SOTHEMACAS:SOT -0.03%74 EV-to-OCF is 30.77 as of Aug. 05, 2026, which is 16% below its 10-year median of 36.65. GuruFocus rates CAS:SOT with a GF Score™ of 74/100 and a GF Value™ of MAD287.78 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,008 Drug Manufacturers companies, SOTHEMA ranks worse than 79.76% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, SOTHEMA's Enterprise Value is MAD14,174 Mil.
SOTHEMA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was MAD461 Mil. Therefore, SOTHEMA's EV-to-OCF for today is 30.77.
The historical rank and industry rank for SOTHEMA's EV-to-OCF or its related term are showing as below:
CAS:SOT'
s EV-to-OCF Range Over the Past 10 Years
Min: 12.64 Med: 36.65 Max: 80.32
Current: 29.99
During the past 13 years, the highest EV-to-OCF of SOTHEMA was 80.32. The lowest was 12.64. And the median was 36.65.
CAS:SOT's EV-to-OCF is ranked worse than 79.76% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.825
vs CAS:SOT: 29.99
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-08-05), SOTHEMA's stock price is MAD369.90.
SOTHEMA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was MAD10.140. Therefore, SOTHEMA's PE Ratio (TTM) for today is 36.48.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SOTHEMA's share price for today is MAD369.90.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SOTHEMA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was MAD10.140.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
SOTHEMA EV-to-OCF Related Terms
SOTHEMA EV-to-OCF Historical Data
* Premium members only.
The historical data trend for SOTHEMA's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, SOTHEMA's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SOTHEMA EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SOTHEMA's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where SOTHEMA's EV-to-OCF falls into.
SOTHEMA's current Enterprise Value is MAD14,174 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SOTHEMA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was MAD461 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOTHEMA (CAS:SOT) has a EV-to-OCF of 30.77 as of Aug. 05, 2026. This is 16% below median its historical median of 36.65. Over the past decade, SOTHEMA's EV-to-OCF has ranged from 12.64 to 80.32. According to the industry distribution chart, SOTHEMA ranks #804 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 79.8%.
Is SOTHEMA's EV-to-OCF too high?
SOTHEMA's current EV-to-OCF of 30.77 is 16% below median its 10-year median of 36.65. Over the past 10 years, this metric has ranged from a low of 12.64 to a high of 80.32. The Drug Manufacturers industry median EV-to-OCF is 10.83. SOTHEMA's value of 30.77 is 184.2% above this industry median. Based on the distribution chart, SOTHEMA ranks #804 out of 1008 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, SOTHEMA has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SOTHEMA's EV-to-OCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, SOTHEMA ranks #804 out of 1008 companies for EV-to-OCF. This places SOTHEMA in the lower half of its industry. The industry median EV-to-OCF is 10.83. SOTHEMA's value of 30.77 is 184.2% above this benchmark. Historically, SOTHEMA's own EV-to-OCF has ranged from 12.64 to 80.32 over the past decade. While the company's 10-year median is 36.65 vs. the industry median of 10.83, SOTHEMA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.83, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SOTHEMA's current EV-to-OCF of 30.77 is 184.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SOTHEMA's current EV-to-OCF is 30.77, which is 16% below median its own 10-year median of 36.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOTHEMA stock overvalued right now?
Based on GuruFocus' analysis, SOTHEMA (CAS:SOT) is currently considered Modestly Overvalued. The stock's GF Value™ is MAD287.78, compared to a current price of MAD369.90 — trading 28.5% above its estimated fair value. The current EV-to-OCF is 30.77, which is 16% below median its 10-year median of 36.65 and 184.2% above the Drug Manufacturers industry median of 10.83. SOTHEMA's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For SOTHEMA (CAS:SOT), the current EV-to-OCF is 30.77 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SOTHEMA (CAS:SOT) Overvalued in 2026?
Based on GuruFocus' analysis, SOTHEMA stock appears to be overvalued.
The current stock price of MAD369.90 is trading 28.5% above its estimated GF Value™ of MAD287.78.
GuruFocus considers SOTHEMA to be Modestly Overvalued.
Key valuation signals for CAS:SOT:
EV-to-OCF: 30.77 (16% below median its 10-year median of 36.65)
GF Value™: MAD287.78 vs. price of MAD369.90 (28.5% above fair value)
Industry Position: 184.2% above the Drug Manufacturers median (#804 of 1008)
No single metric tells the full story. See the CAS:SOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SOTHEMA engages in representation, purchase and sale of pharmaceutical, chemical, health-related, biological, veterinary, plant-based, cosmetic and scented products. The company sells its products in Morocco and overseas.
74GF Score
Get the complete analysis for CAS:SOT
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAS:SOT has been successfully added to your 
